A Cuban initiative for the implementation of pharmacogenomics in Latin America

Pharmacogenomics (PGx) seeks to elucidate interindividual variability in drug response, with the aim of optimizing therapeutic efficacy and minimizing adverse reactions. Although the field has gained scientific momentum in Latin America, its clinical implementation remains limited, largely restricted to academic settings. This short communication presents a regulatory framework—specifically, the Cuban pharmacogenomics guideline—as a foundation for regional implementation. This initiative proposes mapping existing regulations, identifying drug–gene pairs of high clinical impact, and developing a Latin American pharmacogenomic database to guide clinical practice. The Cuban guideline, the first of its kind in the region, covers biomarker validation, ethical considerations, and integration of PGx data into regulatory dossiers. The ultimate goal is to foster equitable, evidence-based personalized medicine in Latin America. Looking ahead, the hope is that personalized medicine will enable both doctors and patients to make more informed decisions about treatment options.